Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat and Oral Paclitaxel in HR+HER2- Advanced Breast Cancer
NCT07441486Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2026
- Primary completion
- Apr 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of entinostat in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
entinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07441486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441486.